Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2011-01-04
2011-01-04
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S139100, C530S300000
Reexamination Certificate
active
07862825
ABSTRACT:
The present disclosure provides methods and uses for controlling tight blood glucose levels in a subject comprising administering an effective amount of a somatostatin inhibitor. The present disclosure provides methods and uses for treating or preventing hypoglycemia in a subject comprising administering an effective amount of a somatostatin inhibitor.
REFERENCES:
patent: 5846934 (1998-12-01), Bass et al.
patent: 6495589 (2002-12-01), Hay et al.
patent: 6696418 (2004-02-01), Hay et al.
patent: 6720330 (2004-04-01), Hay et al.
patent: 6867202 (2005-03-01), Carpino et al.
patent: WO 94/02163 (1994-02-01), None
patent: WO 2006/063465 (2006-06-01), None
Rizza et al., J. Clin. Invest. 64: 62-71, 1979.
Tulipano, G., et al., “Characterization of New Selective Somatostatin Receptor Subtype-2 (sst2) Antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH Release in Anesthetized Male Rats after Short-Term High-Dose Dexamethasone Treatment”, Endocrinology, Apr. 2002, pp. 1218-1224, vol. 143, Issue 4.
Tulipano, G., et al., “The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat”, Regulatory Peptides, 2005, pp. 85-92, vol. 125.
Cejvan, K., et al., “Gliclazide Directly Inhibits Arginine-Induced Glucagon Release”, Diabetes, Dec. 2002, pp. S381-S384, vol. 51, Supplement 3.
Cejvan, K., et al., “Intra-Islet Somatostatin Regulates Glucagon Release via Type 2 Somatostatin Receptors in Rats”, Diabetes, May 2003, pp. 1176-1181, vol. 52.
Brunicardi, F. et al., “Activation of Somatostatin Receptor Subtype 2 Inhibits Insulin Secretion in the Isolated Perfused Human Pancreas”, Pancreas, Nov. 2003, pp. e84-e89, vol. 27, No. 4.
Singh, V., et al., “Characterization of Somatostatin Receptor Subtype-Specific Regulation of Insulin and Glucagon Secretion: An in Vitro Study on Isolated Human Pancreatic Islets”, The Journal of Clinical Endocrinology & Metabolism, Feb. 2007 (First published online Nov. 2006), pp. 673-680, vol. 92, Issue 2.
Chan, J.C.N., et al., “Drug-induced disorders of glucose metabolism, Mechanisms and Management”, Drug Saf., Aug. 1996, pp. 135-157, vol. 15, Issue 2.
Yue, J., et al., “The impact of antagonizing somatostatin actions on glucagon release during hypoglycemia”, CIHR's Funded Research Database, CIHR Doctoral Research Award, 2006. (Abstract).
Efendic Suad
Vranic Mladen
Yue Jessica
Chandra Gyan
Dann Dorfman Herrell & Skillman
Landsman Robert
Netter Robert C.
Rigaut Kathleen D.
LandOfFree
Method of controlling tight blood glucose by somatostatin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of controlling tight blood glucose by somatostatin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of controlling tight blood glucose by somatostatin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2706814